Scarica l'app Stockscreener
14.90
5.37%
0.76
Dopo l'orario di chiusura:
14.68
-0.22
-1.48%
Precedente Chiudi:
$14.14
Aprire:
$13.47
Volume 24 ore:
3.09M
Relative Volume:
2.31
Capitalizzazione di mercato:
$690.53M
Reddito:
$217.11M
Utile/perdita netta:
$-651.19M
Rapporto P/E:
-1.147
EPS:
-12.99
Flusso di cassa netto:
$-387.26M
1 W Prestazione:
+52.66%
1M Prestazione:
+62.13%
6M Prestazione:
+16.22%
1 anno Prestazione:
+22.94%
Intervallo 1D:
$13.36
$15.48
Intervallo di 1 settimana:
$9.78
$15.48
Portata 52W:
$5.00
$16.85
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Nome
Ginkgo Bioworks Holdings Inc
Settore
Industria
Telefono
(877) 442-5362
Indirizzo
27 DRYDOCK AVENUE, BOSTON
Confronta DNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
14.90 | 827.64M | 217.11M | -651.19M | -387.26M | -12.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-15 | Downgrade | BTIG Research | Neutral → Sell |
| 2024-05-10 | Downgrade | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-06-02 | Downgrade | Goldman | Neutral → Sell |
| 2023-05-11 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | Iniziato | Berenberg | Buy |
| 2022-10-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-02 | Ripresa | Cowen | Outperform |
| 2022-02-23 | Iniziato | Goldman | Neutral |
| 2022-02-01 | Iniziato | BofA Securities | Neutral |
| 2022-01-28 | Iniziato | BofA Securities | Buy |
| 2022-01-07 | Iniziato | BTIG Research | Buy |
| 2021-11-29 | Iniziato | Jefferies | Buy |
| 2021-10-13 | Iniziato | Raymond James | Outperform |
| 2021-10-12 | Iniziato | William Blair | Outperform |
| 2021-09-20 | Iniziato | HSBC Securities | Buy |
Mostra tutto
Ginkgo Bioworks Holdings Inc Borsa (DNA) Ultime notizie
How high can Ginkgo Bioworks Holdings Inc. stock price go in 2025Exceptional financial outcomes - jammulinksnews.com
What analysts say about Ginkgo Bioworks Holdings Inc. stockConsistently high yield - Autocar Professional
Is Ginkgo Bioworks Holdings Inc. a good long term investmentSuperior returns - Autocar Professional
Ginkgo Bioworks Holdings Inc. Stock Analysis and ForecastFree Investment Community - jammulinksnews.com
What drives Ginkgo Bioworks Holdings Inc. stock pricePhenomenal capital appreciation - jammulinksnews.com
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Sinks As Market Gains: Here's Why - MSN
Ginkgo Bioworks launches cost-effective ADME profiling service By Investing.com - Investing.com Canada
Ginkgo Bioworks Launches ADME Profiling Service Using Lab Automation, Offering a US-based Operation That Will Match or Beat Pricing Quotes from Chinese or Other International Vendors - MarketScreener
Ginkgo Disrupts Drug Discovery Market with US-Based ADME Service Matching Chinese Prices - Stock Titan
Ginkgo Bioworks Holdings, Inc. (DNA) Outperforms Broader Market: What You Need to Know - sharewise.com
Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Not Quite Adding Up - 富途牛牛
When the Price of (DNA) Talks, People Listen - news.stocktradersdaily.com
Ginkgo Bioworks Holdings (DNA) Shares Fall Despite Market Gains - AInvest
Ginkgo Bioworks (DNA) Shares Soar 5.29% on Q2 Earnings - AInvest
Ginkgo Bioworks (DNA) Soars 18.9%: Is Further Upside Left in the Stock? - MSN
Ginkgo Bioworks Surges 18.9%, Can Further Upside Be Expected? - AInvest
(DNA) On The My Stocks Page - news.stocktradersdaily.com
Ginkgo Bioworks Holdings, Inc.(NYSE: DNA) added to Russell 2500 Index - MarketScreener
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Moves 1.41%: What You Should Know - MSN
Ginkgo Bioworks: Is the Biotech's Undervalued Platform Poised for Scalable Growth? - AInvest
Ginkgo Bioworks stock rises on Hugging Face collaboration for AI drug development - Investing.com Canada
Lobbying Update: $10,000 of GINKGO BIOWORKS lobbying was just disclosed - Nasdaq
Ginkgo Bioworks Holds Annual Shareholder Meeting, Elects Directors - TipRanks
5 "Best" Publicly Traded Synthetic Biology Companies - Securities.io
Ginkgo Bioworks (DNA) Sees 5.4% Increase in Stock Price | DNA Stock News - GuruFocus
Where are the Opportunities in (DNA) - news.stocktradersdaily.com
Ginkgo Bioworks: Hedge Funds Pull Back and Other Important Updates - TradingView
Squarepoint Ops LLC Has $417,000 Stock Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - Defense World
From Promise to Peril: The Downfall of Ginkgo Bioworks - TradingView
Ginkgo Bioworks Holdings Inc Azioni (DNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):